Anti-β-Amyloid (22-35) antibody produced in rabbit

Description

• General description: Rabbit anti-β-amyloid (22-35) antibody specifically recognizes β-amyloid (22-35), β-amyloid (25-35), β-amyloid (1-40) and β-amyloid (1-42) and does not react with β-amyloid (32-35) and β-amyloid (35-25) by ELISA. The antibody detects β-amyloid (1-40) by immunoblotting (approx. 4kDa). Staining of the β-amyloid (1-40) band in immunoblotting is specifically inhibited by the immunizing peptide.
• Immunogen: synthetic peptide corresponding to amino acids 22-35 of human β-amyloid (1-40) fragment, conjugated to KLH. This sequence corresponds to amino acids 693-706 of the human amyloid precursor protein APP, and is identical in mouse and rat APP.
• Application: Rabbit anti-β-amyloid (22-35) antibody can be used for ELISA at a concentration of 0.2-0.4μg/mL using β-amyloid peptide (22-35). The product can also be used for western blot at 0.25-0.5μg/mL using β-amyloid peptide (1-40).
• Biochem/physiol Actions: Secreted Aβ lead to synaptic and neuritic compromise and glial activation. Aggregates of amyloid β peptide are found deposited in the brains of Alzheimer′s patients. Aβ(25-35) and Aβ(22-35) fragments are highly toxic segments of β-amyloid peptides that promote inflammatory processes in astrocytes and fibrillary aggregation of Aβ, thus representing a promising therapeutic target for Alzheimer′s.
• Physical form: Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide and 1% bovine serum albumin.
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.